Jody L. Janecek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jody L. Janecek has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Sabarinathan Ramachandran
Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
3 shared publications - Laura Hocum Stone
Department of Surgery, University of Minnesota, Minneapolis, MN, USA
2 shared publications - Melanie L. Graham
Preclinical Research Center, Department of Surgery, University of Minnesota, Minneapolis, MN, USA
2 shared publications - Parthasarathy Rangarajan
Department of Surgery, University of Minnesota, Minneapolis, MN, USA
2 shared publications Alina Baum
Regeneron Pharmaceuticals Inc, Tarrytown, NY 10591, USA
1 shared publicationAline M.S. Yamashita
Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in Stem Cell Reports
- Vol. 21 (11) , 103119
Donor-intrinsic regenerative potential outweighs histocompatibility in iPSC-derived skeletal muscle engraftment in nonhuman primates
- 15 October 2026
- Published by Elsevier in Stem Cell Reports
- Vol. 21 (11) , 103119
Open AccessDonor-intrinsic regenerative potential outweighs histocompatibility in iPSC-derived skeletal muscle engraftment in nonhuman primates
- Open Access
- 5 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (1) , eadi4919
A bioengineered artificial interstitium supports long-term islet xenograft survival in nonhuman primates without immunosuppression
Cell-based therapies hold promise for many chronic conditions; however, the continued need for immunosuppression along with challenges in replacing cells to improve durability or retrieving cells for safety are major obstacles. We subcutaneously implanted a device engineered to exploit the innate transcapillary hydrostatic and colloid osmotic pressure generating ultrafiltrate to mimic interstitium. Long-term stable accumulation of ultrafiltrate was achieved in both rodents and nonhuman primates (NHPs) that was chemically similar to serum and achieved capillary blood oxygen concentration. The majority of adult pig islet grafts transplanted in non-immunosuppressed NHPs resulted in xenograft survival >100 days. Stable cytokine levels, normal neutrophil to lymphocyte ratio, and a lack of immune cell infiltration demonstrated successful immunoprotection and averted typical systemic changes related to xenograft transplant, especially inflammation. This approach eliminates the need for immunosuppression and permits percutaneous access for loading, reloading, biopsy, and recovery to de-risk the use of “unlimited” xenogeneic cell sources to realize widespread clinical translation of cell-based therapies.
- 5 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (1) , eadi4919
Open AccessA bioengineered artificial interstitium supports long-term islet xenograft survival in nonhuman primates without immunosuppression
Cell-based therapies hold promise for many chronic conditions; however, the continued need for immunosuppression along with challenges in replacing cells to improve durability or retrieving cells for safety are major obstacles. We subcutaneously implanted a device engineered to exploit the innate transcapillary hydrostatic and colloid osmotic pressure generating ultrafiltrate to mimic interstitium. Long-term stable accumulation of ultrafiltrate was achieved in both rodents and nonhuman primates (NHPs) that was chemically similar to serum and achieved capillary blood oxygen concentration. The majority of adult pig islet grafts transplanted in non-immunosuppressed NHPs resulted in xenograft survival >100 days. Stable cytokine levels, normal neutrophil to lymphocyte ratio, and a lack of immune cell infiltration demonstrated successful immunoprotection and averted typical systemic changes related to xenograft transplant, especially inflammation. This approach eliminates the need for immunosuppression and permits percutaneous access for loading, reloading, biopsy, and recovery to de-risk the use of “unlimited” xenogeneic cell sources to realize widespread clinical translation of cell-based therapies.